The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLMC 2020 | The future of multiple myeloma treatment
Joseph Mikhael, MD, MEd, FRCPC, FACP, Translational Genomics Research Institute (TGen), City of Hope Cancer Center, CA, outlines the future of multiple myeloma (MM) treatment, highlighting the significance of developing drugs with new mechanisms of action, such as anti-BCMA (B-cell maturation antigen) therapies, chimeric antigen receptor (CAR) T-cell therapies and bispecific antibody therapies, and the potential approval of the first CAR T-cell therapy and melphalan flufenamide in the near future. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Disclosures
Consultant for Amgen, BMS, Karyopharm, Janseen, Sanofi and Takeda
